Sodium-glucose co-transporter2-inhibitors (SGLT2-i) have been shown to significantly reduce the composite endpoint of cardiovascular death and hospitalisation for heart failure in patients with chronic heart failure independent of the left-ventricular ejection fraction (LV-EF) or the presence of diabetes1–5. This evidence concerns the gene SLC5A2 and heart failure.